Compare CEVA & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CEVA | GOSS |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.9M | 615.7M |
| IPO Year | 2002 | 2018 |
| Metric | CEVA | GOSS |
|---|---|---|
| Price | $19.69 | $2.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $33.25 | $8.83 |
| AVG Volume (30 Days) | 339.9K | ★ 5.3M |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.45 | ★ 78.81 |
| EPS | ★ N/A | N/A |
| Revenue | $87,507,000.00 | ★ $114,701,000.00 |
| Revenue This Year | $14.97 | N/A |
| Revenue Next Year | $12.74 | $6.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 20.45 | N/A |
| 52 Week Low | $18.23 | $0.76 |
| 52 Week High | $36.95 | $3.87 |
| Indicator | CEVA | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 34.84 |
| Support Level | $19.30 | $2.24 |
| Resistance Level | $24.00 | $2.50 |
| Average True Range (ATR) | 1.25 | 0.21 |
| MACD | -0.23 | -0.01 |
| Stochastic Oscillator | 8.21 | 1.53 |
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.